| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
Olsen Per Wold last filed a Form 4 in January 2023, as Director at AMRN. The filings on record cover 2 companies. Olsen Per Wold's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 102,060 shares of GILD. The GILD filings lean toward selling, a net 46,910 shares.
Olsen Per Wold has 14 Form 4 filings on record from May 2017 to January 2023, across 2 companies: Director at Amarin Corp Plc\uk (AMRN), 2022–2023; Director at Gilead Sciences (GILD), 2017–2021.
The 25 reported transactions were 12 option or other derivative awards, 9 option exercises, 3 open-market sales and 1 open-market purchase.
Counted by filing, the open-market trades come to 1 purchase worth about $93K and 2 sales worth about $3.2M.
The only open-market purchase was 55,000 shares of AMRN at an average $1.69 on June 13, 2022, about $93K. Twelve months later AMRN was down 25%.
The largest open-market sale was 42,002 shares of GILD at an average $68.55 on February 7, 2020, about $2.9M.
Shares as reported in the last Form 4 for each company; the most recent is from January 2023. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.